MedTrace Logo

Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo

NCT04941833 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-31

No results posted yet for this study

Summary

Use of the oral desogestrel compared with placebo for preoperative treatment of endometrioma in the patient who underwent to surgery in next 3 months The result will be evaluated on cyst diameter, the associated pain and side effect of the oral desogestrel.

Conditions

  • Endometrioma

Interventions

DRUG

Desogestrel Oral Tablet

Cerazette is the brand name of the desogestrel which contain of 0.075 mg of desogestrel

Sponsors & Collaborators

  • Department of Medical Services Ministry of Public Health of Thailand

    lead OTHER_GOV

Principal Investigators

  • Ratchadaporn Roekyindee, MD · Department of Medical Services Ministry of Public Health of Thailand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-07-31
Completion
2022-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04941833 on ClinicalTrials.gov